487 related articles for article (PubMed ID: 26246479)
1. Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
Huang TC; Hsu CH; Lin CC; Tu YK
Jpn J Clin Oncol; 2015 Nov; 45(11):1023-8. PubMed ID: 26246479
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
4. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
8. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
9. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
10. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
Messager M; Mirabel X; Tresch E; Paumier A; Vendrely V; Dahan L; Glehen O; Vasseur F; Lacornerie T; Piessen G; El Hajbi F; Robb WB; Clisant S; Kramar A; Mariette C; Adenis A
BMC Cancer; 2016 May; 16():318. PubMed ID: 27194176
[TBL] [Abstract][Full Text] [Related]
11. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
12. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
[TBL] [Abstract][Full Text] [Related]
13. EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
DeWitt JM; Murthy SK; Ardhanari R; DuVall GA; Wallner G; Litka P; Daugherty C; Fowers K
Gastrointest Endosc; 2017 Jul; 86(1):140-149. PubMed ID: 27890801
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
15. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).
van Heijl M; van Lanschot JJ; Koppert LB; van Berge Henegouwen MI; Muller K; Steyerberg EW; van Dekken H; Wijnhoven BP; Tilanus HW; Richel DJ; Busch OR; Bartelsman JF; Koning CC; Offerhaus GJ; van der Gaast A
BMC Surg; 2008 Nov; 8():21. PubMed ID: 19036143
[TBL] [Abstract][Full Text] [Related]
19. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
Liu T; Ding S; Dang J; Wang H; Chen J; Li G
Radiat Oncol; 2019 Oct; 14(1):176. PubMed ID: 31619265
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
